The subsidiary of Garden Bio (300401.SZ) has obtained the registration certificate for the sustained-release tablet of Upatinib.

Tencent Finance News, Huayuan Biological (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Huayuan Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for "Upatinib Sustained-Release Tablets". Upatinib Sustained-Release Tablets are mainly used for moderate to severe atopic dermatitis, moderate to severe active rheumatoid arthritis, active psoriatic arthritis, moderate to severe ulcerative colitis, etc.